Inhaled corticosteroids in treatment of patients with intermittent bronchial asthma: yes or no? Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005
Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis Source: ERJ Open Res, 7 (3) 00321-2021; 10.1183/23120541.00321-2021 Year: 2021
Alveolar absorption and systemic bioactivity of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 13s Year: 2004
Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015
Methotrexate in the treatment of the chronic form of pulmonary and extra - pulmonary sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 712s Year: 2004
Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard Source: Eur Respir J 2015; 45: 1208-1210 Year: 2015
Triple therapy with Fluticasone furoate/Umeclidinium/Vilanterol compared with dual bronchodilation or triple therapy with inhaled corticosteroids/dual bronchodilation in patients with chronic obstructive pulmonary disease Source: Virtual Congress 2020 – Investigations of COPD Year: 2020
Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler(R) Source: Eur Respir J 2002; 19: 1058-1063 Year: 2002
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: 1075 Year: 2004
Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial Source: Eur Respir J, 57 (1) 2000348; 10.1183/13993003.00348-2020 Year: 2021
The therapy of idiopathic pulmonary fibrosis: what is next? Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019 Year: 2019
Comparison of prednisolone and budesonide in the treatment of pulmonary sarcoidosis Source: Eur Respir J 2005; 26: Suppl. 49, 80s Year: 2005
Safety of salmeterol / fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
Late Breaking Abstract - Pharmacokinetics (PK) of nintedanib with add-on pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): results from INJOURNEY Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017
Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017
Is there any point in treatment of patients with chronic obstructive pulmonary diseases with salmeterol and ipratropium bromide, alone and in combination? Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002
Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study Source: Eur Respir J 2012; 39: 772-775 Year: 2012
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006
Transition from IV to nebulised iloprost therapy as a short and long term treatment for pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016